| IMPORTANCE OF TIMING OF MATERNAL TDAP IMMUNIZATION AND PROTECTION OF YOUNG INFANTS. | |
| | |
MedLine Citation:
|
PMID: 23097585 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Background. Pertussis booster vaccine (Tdap) recommendations assume that pertussis-specific antibodies in women immunized preconception, during or after previous pregnancies, persist at sufficient levels to protect newborn infants.Methods. Pertussis-specific IgG was measured by IgG-specific enzyme-linked immunosorbant assay in maternal-umbilical cord serum pairs where mothers received Tdap during the prior 2 years. Geometric mean concentrations (GMCs) of pertussis antibodies and cord: maternal GMC ratios were calculated.Results. One hundred-five mothers (mean age 25.3 years [15.3-38.4]; mean gestation 39 weeks [37-43]) immunized with Tdap vaccine a mean of 13.7 months (2.3-23.9) previously were included; 72 (69%) had received Tdap postpartum, 31 at a routine healthcare visit and 2 as contacts of another newborn. There was no difference in GMCs for pertussis-specific IgG in maternal delivery or infant cord sera for women immunized before (86) or during early pregnancy (19). Placental transport of antibodies was 121% to 186% from mothers immunized before and during pregnancy, respectively. Estimated GMC of IgG to PT was < 5 EU/ml at infant age 2 months (start of infant immunization series). More infants of mothers immunized during pregnancy had PT levels estimated to be more than the lower limit of quantitation of the assay (4 EU/ml) through age 2 months (52% versus 38%; P = 0.34).Conclusions. Infants of mothers immunized preconception or in early pregnancy have insufficient pertussis-specific antibodies to protect against infection. Maternal immunization during the third trimester, immunization of other infant contacts, and reimmunization during subsequent pregnancies may be necessary. |
| | |
Authors:
|
C Mary Healy; Marcia A Rench; Carol J Baker |
Related Documents
:
|
15814135 - Pharmacokinetic behaviour of acp gel, an autocrosslinked hyaluronan derivative, after i... 23459375 - Successful treatment of refractory immune thrombocytopenia with rituximab in a 10-week-... 15134195 - Phenotype of the triplo-lethal locus of drosophila melanogaster and its suppression by ... 23541625 - A cross-sectional examination of the relationships between caregiver proximal soothing ... 9418515 - Breast-feeding support in a neonatal surgical unit. 18762515 - Heritability of bronchopulmonary dysplasia, defined according to the consensus statemen... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-24 |
Journal Detail:
|
Title: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Volume: - ISSN: 1537-6591 ISO Abbreviation: Clin. Infect. Dis. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9203213 Medline TA: Clin Infect Dis Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Center for Vaccine Awareness and Research, Texas Children's Hospital. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Frequency, severity and prediction of tuberculous meningitis immune reconstitution inflammatory synd...
Next Document: National Outbreak of Type A Foodborne Botulism Associated with a Widely Distributed Commercially Can...